Decoding the message of Intercept’s Complete Response Letter
Former FDA Director Brian Harvey joins the Surfers to discuss what obeticholic acid’s rejection might mean for other NASH medicines in development. Is this the end of accelerated approvals? Does it simply mean we need better drugs? Join the debate